Buckingham Strategic Wealth’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Buckingham Strategic Wealth’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	-$7K	–	671
2022 Q3	$7K	Hold	1	–	–	﹤0.01%	604
2022 Q2	$16K	Hold	1	–	–	﹤0.01%	602
2022 Q1	$53K	Hold	1	–	–	﹤0.01%	586
2021 Q4	$43K	Hold	1	–	–	﹤0.01%	590
2021 Q3	$54K	Hold	1	–	–	﹤0.01%	584
2021 Q2	$71K	Buy	+1	New	+$97.5K	﹤0.01%	581

Other funds holding PBLA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFG

Oxford Financial Group Carmel, Indiana $1.86B AUM 19.25% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Buckingham Strategic Wealth's PBLA Position: Q4 2022 in Review

Buckingham Strategic Wealth sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q4 2022, closing a stake of 1 share — an estimated $7K sold.

Buckingham Strategic Wealth first reported a position in PBLA in Q2 2021 and held it in 6 quarters. The position peaked at $71K in Q2 2021. 10 funds tracked by Wall St. Rank hold PBLA as of Q4 2022.

Buckingham Strategic Wealth reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Buckingham Strategic Wealth sold 1 Panbela Therapeutics, Inc. Common Stock share in Q4 2022, an estimated $7K.
Buckingham Strategic Wealth first reported a position in Panbela Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Buckingham Strategic Wealth's Panbela Therapeutics, Inc. Common Stock position peaked at $71K in Q2 2021.
10 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Buckingham Strategic Wealth's 13F filing for Q4 2022, filed 13 Feb 2023.